Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands
Publication date
2017-09-13
Authors
ter Heine, Rob
Frederix, Gerardus W.J.
Geenen, Joost W.
Hövels, Anke M.
van Vulpen, Marco
Kooistra, Anko
De Klerk, John Mh
Bloemendal, Haiko J
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
AIM: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). METHODS: We performed a bottom-up cost of illness study in The Netherlands. RESULTS: A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912. CONCLUSION: Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.
Keywords
bone metastases, cost of illness, prostate cancer, radionuclide therapy, skeletal-related ecents, Taverne, SDG 3 - Good Health and Well-being
Citation
ter Heine, R, Frederix, G W, Geenen, J W, Hövels, A M, van Vulpen, M, Kooistra, A, De Klerk, J M & Bloemendal, H J 2017, 'Cost of illness of metastatic prostate cancer : a perspective of costs for new treatment options in The Netherlands', Comparative Hepatology, vol. 6, no. 7, pp. 575-581. https://doi.org/10.2217/cer-2017-0026